[144] CYTOKINETICS INC SEC Filing

Rhea-AI Filing Summary

Form 144 notice for CYTK reports a proposed sale of 15,000 common shares through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $824,400 and an approximate sale date of 10/01/2025. The shares were acquired as restricted stock units on 03/06/2021. The filing lists five prior 10b5-1 sales by the same person during Jul–Sep 2025 totalling 25,000 shares and gross proceeds shown for each trade. The filer certifies no undisclosed material adverse information and that the sale complies with Rule 144 and any applicable 10b5-1 plan.

Positive

• Transparent disclosure of proposed sale details (shares, aggregate value, broker, exchange, and acquisition method)
• Compliance with Rule 144 and 10b5-1 protocols is documented, including prior sales history and seller certification

Negative

• Insider selling activity continues: proposed 15,000-share sale plus 25,000 shares sold in Jul–Sep 2025 could increase share supply
• No plan adoption date or signature details are included in the provided text, limiting context on timing of any 10b5-1 plan

Insights

Securities Analyst

TL;DR: Insider plans to sell 15,000 shares (~$824k) under Rule 144; recent 10b5-1 activity shows ongoing dispositions.

The filing documents a routine Rule 144 sale of shares originally granted as restricted stock units in 2021. The proposed trade size and disclosed aggregate market value are explicit, and the use of Morgan Stanley Smith Barney indicates brokered execution. The historical 10b5-1 sales (five transactions totalling 25,000 shares across Jul–Sep 2025) suggest a continuing divestiture pattern. This is a disclosure of insider liquidity rather than new corporate events; it informs supply-side dynamics but contains no operational or financial performance data.

Corporate Governance Expert

TL;DR: Filing is a compliance disclosure showing permitted insider sales; no indication of undisclosed adverse information.

The signer affirms under penalty that they possess no material nonpublic information and cites reliance on Rule 10b5-1 for prior trades where applicable. The disclosure of acquisition date, nature (RSUs), and prior sale history aligns with governance transparency best practices. There is no mention of plan adoption date or additional restrictions in this filing text, so reviewers should rely solely on the provided entries when assessing insider conduct.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	15000	824400.00	119657156	10/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/06/2021	Restricted Stock Units	Issuer			15000	03/06/2021	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for ROBERT BLUM 350 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080	Common	09/15/2025	5000	248835.00
10b5-1 Sales for ROBERT BLUM 350 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080	Common	09/02/2025	5000	243804.00
10b5-1 Sales for ROBERT BLUM 350 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080	Common	08/15/2025	5000	192079.50
10b5-1 Sales for ROBERT BLUM 350 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080	Common	07/29/2025	5000	182247.50
10b5-1 Sales for ROBERT BLUM 350 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080	Common	07/14/2025	5000	190738.50

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for CYTK report?

It reports a proposed sale of 15,000 common shares on NASDAQ with an aggregate market value of $824,400, to occur approximately on 10/01/2025.

How were the shares acquired that are being sold?

The 15,000 shares were acquired as restricted stock units on 03/06/2021 and payment/nature is listed as N/A in this filing.

Has the seller made recent sales of CYTK shares?

Yes. The filing lists five 10b5-1 sales in Jul–Sep 2025 totaling 25,000 shares with gross proceeds disclosed for each trade.

Through which broker will the proposed sale be executed?

Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, New York, NY) is listed as the broker.

Does the filing indicate any undisclosed material information?

The filer certifies they do not know any material adverse information that has not been publicly disclosed as part of the Form 144 signature statement.